Stocks Overview

LAST PRICE
1.8100
TODAY'S CHANGE (%)
Trending Down-0.1300 (-6.7010%)

Bid / Lots
1.8200/ 1
Ask / Lots
1.9100/ 4
Open / Previous Close
1.9500 / 1.9400
Day Range
Low 1.8100
High 1.9500
52 Week Range
Low 1.7700
High 11.4100
Volume
425,371
below average

Search Criteria

Click on magnifying glass icon to search

Search Criteria - - - Stocks (0)
Company	Country	Symbol

TSX Comp
TSX Venture
DJIA
S&P 500
NASDAQ

Price Comparison Graph. See accessible table below

1 Day Comparison Chart Accessibility Table. Thursday's close: 1.94
Time	Volume	VRCA
09:32 ET	32093	1.9376
09:34 ET	500	1.91
09:38 ET	4593	1.88
09:39 ET	234	1.8874
09:45 ET	504	1.917
09:48 ET	100	1.89
09:57 ET	1000	1.9
09:59 ET	13430	1.8529
10:01 ET	1884	1.85
10:03 ET	268	1.8593
10:06 ET	4480	1.8448
10:08 ET	3215	1.85
10:10 ET	500	1.8499
10:12 ET	5276	1.85
10:14 ET	3448	1.86
10:15 ET	622	1.8693
10:19 ET	136	1.87
10:21 ET	136	1.8509
10:24 ET	1577	1.8606
10:28 ET	545	1.85
10:32 ET	624	1.847
10:39 ET	600	1.86
10:44 ET	100	1.85
10:46 ET	5468	1.85
10:50 ET	104	1.8595
11:04 ET	1300	1.85
11:08 ET	300	1.84
11:09 ET	1900	1.83
11:11 ET	2335	1.83
11:13 ET	667	1.825
11:15 ET	700	1.82
11:18 ET	1600	1.8225
11:20 ET	1412	1.83
11:22 ET	101	1.845
11:24 ET	269	1.84
11:33 ET	800	1.83
11:36 ET	100	1.83
11:38 ET	200	1.83
11:42 ET	371	1.8393
11:44 ET	200	1.84
11:45 ET	190	1.84
11:47 ET	120	1.85
11:49 ET	2500	1.845
11:51 ET	200	1.84
11:54 ET	105	1.85
11:56 ET	100	1.84
11:58 ET	600	1.845
12:00 ET	100	1.8406
12:02 ET	100	1.84
12:07 ET	300	1.84
12:16 ET	100	1.84
12:18 ET	10200	1.84
12:23 ET	100	1.835
12:25 ET	100	1.84
12:27 ET	108	1.8393
12:34 ET	100	1.83
12:36 ET	100	1.83
12:38 ET	1350	1.8309
12:39 ET	2640	1.83
12:45 ET	100	1.82
12:50 ET	12812	1.8303
12:52 ET	100	1.82
12:56 ET	300	1.82
12:57 ET	100	1.82
12:59 ET	600	1.827
01:01 ET	400	1.825
01:03 ET	4826	1.835
01:06 ET	200	1.835
01:08 ET	3116	1.84
01:10 ET	850	1.855
01:14 ET	350	1.865
01:15 ET	100	1.865
01:17 ET	700	1.85
01:19 ET	300	1.8593
01:24 ET	400	1.85
01:28 ET	165	1.8493
01:33 ET	300	1.84
01:35 ET	801	1.844
01:37 ET	2399	1.8499
01:42 ET	100	1.84
01:44 ET	500	1.84
01:48 ET	1004	1.83
01:50 ET	200	1.83
01:55 ET	300	1.83
01:57 ET	100	1.83
02:00 ET	100	1.83
02:02 ET	100	1.83
02:04 ET	1475	1.838
02:09 ET	100	1.83
02:11 ET	100	1.83
02:13 ET	400	1.83
02:18 ET	100	1.83
02:26 ET	2092	1.83
02:29 ET	822	1.8306
02:31 ET	100	1.83
02:36 ET	200	1.83
02:38 ET	100	1.8311
02:40 ET	1849	1.83
02:44 ET	200	1.835
02:49 ET	100	1.835
02:54 ET	100	1.835
02:56 ET	3311	1.8399
02:58 ET	1832	1.84
03:00 ET	4000	1.8397
03:05 ET	360	1.8491
03:09 ET	300	1.846
03:20 ET	100	1.85
03:21 ET	150	1.8407
03:23 ET	600	1.84
03:25 ET	200	1.84
03:32 ET	100	1.84
03:36 ET	1603	1.84
03:38 ET	100	1.84
03:39 ET	1744	1.84
03:41 ET	300	1.84
03:48 ET	200	1.84
03:50 ET	4861	1.82
03:52 ET	4079	1.82
03:54 ET	300	1.825
03:56 ET	500	1.82
03:57 ET	18682	1.81
03:59 ET	176594	1.81

Data delayed at least 15 minutes.

Today
- Notice to Long-Term Shareholders of Verrica Pharmaceuticals, Inc. (VRCA), from 13 hours ago by Dow Jones
  13 hours ago by Dow Jones
Sep 13, 2024
- VERRICA PHARMACEUTICALS INVESTIGATION CONTINUED by Former Louisiana Attorney General: Kahn Swick & Foti, LLC Continues to Investigate the Officers and Directors of Verrica Pharmaceuticals Inc. - VRCA, from 4:57PM ET on Friday Sep 13, 2024 by Dow Jones
  4:57PM ET on Friday Sep 13, 2024 by Dow Jones
Sep 5, 2024
- Grabar Law Office Investigates Claims on Behalf of Shareholders of Verrica Pharmaceuticals, Inc. (VRCA) After Securities Fraud Class Action Survives Motion to Dismiss, from 5:57PM ET on Thursday Sep 05, 2024 by Dow Jones
  5:57PM ET on Thursday Sep 05, 2024 by Dow Jones
Sep 4, 2024
- Verrica Pharmaceuticals to Participate in the H.C. Wainwright 26th Annual Global Investment Conference in New York, from 7:30AM ET on Wednesday Sep 04, 2024 by Dow Jones
  7:30AM ET on Wednesday Sep 04, 2024 by Dow Jones

0 New Today

Industry Peers Overview Table
Company sortable	Market Cap sortable	P/E Ratio (TTM) sortable	EPS Growth (5yr) sortable
United StatesVRCA Verrica Pharmaceuticals Inc	82.8M	-1.0x	---
United StatesIMAB I-Mab	89.8M	0.0x	---
United StatesZHYBF Zhong Yuan Bio-Technology Holdings Ltd	88.2M	391.4x	---
United StatesCLRB Cellectar Biosciences Inc	75.6M	-0.7x	---
United StatesEDTXF Spectral Medical Inc	130.3M	-9.7x	---
United StatesUG United-Guardian Inc	66.8M	20.8x	-9.92%
As of 2024-09-20

Verrica Pharmaceuticals Inc. is a dermatology therapeutics company. The Company is focused on developing and commercializing treatments for skin diseases. Its product pipeline consists of three product candidates: YCANTH, VP-315 and VP-103. YCANTH is a proprietary drug-device combination that contains a GMP-controlled formulation of cantharidin. We are also developing YCANTH for potential follow-on indications for the treatment of common warts and external genital warts. In addition, the Company is also developing YCANTH for the treatment of external genital warts, or external genital warts EGW. Its second candidate, VP-315, is an oncolytic peptide-based injectable therapy for the potential treatment of dermatology oncologic conditions, including basal cell carcinoma, non-metastatic melanoma, and non-metastatic Merkel cell carcinoma. VP-103, a second cantharidin based drug device combination for the potential treatment of plantar warts.

Contact Information

Headquarters: 10 N High St Ste 200WEST CHESTER, PA, United States 19380-3014
Phone: 484-453-3300
Fax: 302-636-5454

Executives

Chairman of the Board: Paul Manning
President, Chief Executive Officer, Director: Ted White
Chief Financial Officer: P. Terence Kohler
General Counsel, Company Secretary, Chief Legal Office: Christopher Hayes
Chief Medical Officer: Gary Goldenberg

Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.

Open a New Account, or Login if you're a client.

You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.

Open a New Account, or Login if you're a client.

Skip section

INK Company InsiderDetailed daily analysis of insider activity and holdings for stocks and income trusts listed in Canada, based on filings from SEDI®.

Fundamentals Table
Market Cap	$82.8M
Revenue (TTM)	$13.9M
Shares Outstanding	42.7M
Dividend Yield	0.00%
Annual Dividend Rate	---
Ex-Dividend Date	01-01-01
Pay Date	01-01-01
Beta	1.47
EPS	$-1.88
Book Value	$0.47
P/E Ratio	-1.0x
Price/Sales (TTM)	6.0
Price/Cash Flow (TTM)	---
Operating Margin	-581.38%

*GAAP = prior to non-GAAP analyst adjusted earnings.

Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.

Open a New Account, or Login if you're a client.

Verrica Pharmaceuticals Inc
NASDAQ:VRCAUnited States

Search Criteria

Charts

Recent News

Today

Notice to Long-Term Shareholders of Verrica Pharmaceuticals, Inc. (VRCA), from 13 hours ago by Dow Jones

Sep 13, 2024

VERRICA PHARMACEUTICALS INVESTIGATION CONTINUED by Former Louisiana Attorney General: Kahn Swick & Foti, LLC Continues to Investigate the Officers and Directors of Verrica Pharmaceuticals Inc. - VRCA, from 4:57PM ET on Friday Sep 13, 2024 by Dow Jones

Sep 5, 2024

Grabar Law Office Investigates Claims on Behalf of Shareholders of Verrica Pharmaceuticals, Inc. (VRCA) After Securities Fraud Class Action Survives Motion to Dismiss, from 5:57PM ET on Thursday Sep 05, 2024 by Dow Jones

Sep 4, 2024

Verrica Pharmaceuticals to Participate in the H.C. Wainwright 26th Annual Global Investment Conference in New York, from 7:30AM ET on Wednesday Sep 04, 2024 by Dow Jones

Pharmaceuticals - Diversified Industry Peers

Company Information

Contact Information

Executives

Ratings

Reports

Fundamentals

Calendar